Effect of kurarinol on peripheral blood CTL surface PD-1 expression of patients with chronic hepatitis B.
- Author:
Yin-Fang ZHU
1
;
Xi-Bing GU
;
Xiao-Juan YANG
;
Zhong HUA
;
Zhong-Hua LU
;
Bo ZANG
;
Hang-Yuan WU
;
Yi-Ming JIANG
;
Hao-Kun CHEN
;
Hao PEI
;
Yue-Qin XU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Drugs, Chinese Herbal; administration & dosage; Flavonoids; administration & dosage; Gene Expression; drug effects; Hepatitis B virus; physiology; Hepatitis B, Chronic; drug therapy; genetics; immunology; virology; Humans; Male; Middle Aged; Programmed Cell Death 1 Receptor; genetics; immunology; T-Lymphocytes, Cytotoxic; drug effects; immunology; Treatment Outcome; Young Adult
- From: Chinese Journal of Experimental and Clinical Virology 2012;26(6):446-449
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the anti-viral mechanism of kurarinol through studying its influence on cytotoxic T lymphocyte (CTL) surface program death receptor-1 (PD-1) expression of patients with chronic hepatitis B (CHB).
METHODS69 cases of CHB, HBV DNA > or = 10(4) copies/ml, HBeAg positive, human leukocyte antigen (HLA)-A2 positive, alanine aminotransferase (ALT) > 2 x upper limit of normal value(ULN).69 cases were randomly divided into two groups:34 cases in treatment group,600 mg of kurarinol glucose injection was used for intravenous dripping, once a day, one month later, 200 mg of kurarinol capsule was used orally,three times a day and 200 mg of silybin meglumine tablet was used orally, three times a day. 35 cases in control group, only silibin meglumine tablet was used, method and dosage were the same as those of treatment group. Three months later, their peripheral blood HBV specific CTL surface PD-1 expression, non-specific CTL surface PD-1 expression and level of HBV specific CTL,HBV DNA and HBeAg negative rate and liver functions were analyzed and compared.
RESULTS3 months after treatment, peripheral blood HBV specific CTL surface PD-1 expression of the treatment group decreased compared with that before treatment (t = 2.39, P < 0.05), it also decreased compared with that of the control group 3 months after treatment (t = 2.26, P < 0.05), HBV specific CTL increased compared with that before treatment( t = 3.01, P < 0.01), it also increased compared with that of the control group after treatment (t = 2.65, P < 0.05). There was no significant difference of non-specific CTL surface PD-1 expression compared with that before treatment (P > 0.05), and there was no significant difference compared with that of the control group after treatment (P > 0.05). HBV DNA of 11 cases (32.5%) turned negative ( HBV DNA < 500 copies/ ml), higher than that of the control group after treatment (2 cases, 5.71%) chi2 = 7.99, P < 0.01, HBeAg of 9 cases (26.47%) turned negative, higher than that of the control group after treatment (1 case, 2.86%), chi2 = 7.75, P < 0.01.
CONCLUSIONKurarinol can increase level of HBV specific CTL by down-regulating peripheral blood HBV specific CTL surface PD-1 expression of CHB patients, which may be one of the possible mechanisms that kurarinol can remove or inhibit HBV of CHB patients.
